Shopping Cart
Remove All
Your shopping cart is currently empty
TYRA-300 is an oral and selective FGFR3 inhibitor with an IC50 value of 11 nM and 25-fold, 14-fold, and 36-fold selectivity for FGFR1, FGFR2, and FGFR4, respectively, in the Ba/F3 cell line for the treatment of metastatic uroepithelial carcinomas (mUCs) and chondrodysplasia.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $392 | In Stock | In Stock | |
| 5 mg | $726 | In Stock | In Stock | |
| 10 mg | $987 | In Stock | In Stock | |
| 25 mg | $1,620 | - | In Stock | |
| 50 mg | $2,190 | - | In Stock | |
| 100 mg | $2,960 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $893 | - | In Stock |
| Description | TYRA-300 is an oral and selective FGFR3 inhibitor with an IC50 value of 11 nM and 25-fold, 14-fold, and 36-fold selectivity for FGFR1, FGFR2, and FGFR4, respectively, in the Ba/F3 cell line for the treatment of metastatic uroepithelial carcinomas (mUCs) and chondrodysplasia. |
| Targets&IC50 | FGFR4:4045 nM, FGFR3:11 nM, FGFR1:278 nM, FGFR2:157 nM |
| Synonyms | TYRA-300-B01, TYRA300 |
| Molecular Weight | 559.47 |
| Formula | C25H24Cl2N6O3S |
| Cas No. | 2800223-30-5 |
| Smiles | S(C)(=O)(=O)N1CC2(CN(C2)C3=CC=C(C=N3)C=4C=5C(NN4)=CC=C(O[C@H](C)C=6C(Cl)=CN=CC6Cl)C5)C1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (142.99 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.